Risperidone and Refusal to Eat After Traumatic Brain Injury
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
SIR: The major clusters of psychiatric symptoms related to traumatic brain injury (TBI) are those of behavioral sequelae and of cognitive impairment. Clinically, these psychiatric symptoms are a very difficult barrier to overcome in rehabilitation programs.
We report a case of a brain-injured patient with refusal to eat who responded to risperidone after failing to respond to other treatments.
Case Report
>A 66-year-old man without any past psychiatric history suffered traumatic brain injury following a traffic accident and was thereafter admitted to a hospital. A left orbitofrontal lobe contusion and a traumatic subarachnoid hemorrhage were documented by a CT scan. Neurosurgical intervention was not indicated in this case.After the head injury, the patient developed psychiatric symptoms. His behavioral symptoms included increased aggression, agitation with yelling, and depression. Cognitive problems involved decreased attention and problems with memory. Residual deficits also included moderate right hemiparesis. The neurobehavioral deficits continued to be a very difficult barrier to rehabilitative progress. Medication trials with conventional antipsychotics (haloperidol, chlorpromazine) at therapeutic dosages were not effective.In addition, about a month after the traffic accident, he started to refuse eating and would not cooperate with any medical treatment. He actively resisted requests to participate in rehabilitation. He refused to allow either food or medicine to be placed in his mouth. He lost weight, and undernourishment made his rehabilitative progress even more difficult. Medication trials with sulpiride 150 mg/day, amantadine 300 mg/day, fluvoxamine 150 mg/day, and some benzodiazepines did not improve the situation.He was referred to our hospital 2 months after the traffic accident. At that time, risperidone was initiated at a dose of 2 mg/day, and 3 weeks later it was increased to 3 mg/day. About a week after the initiation of risperidone, he began to calm down and showed a greatly reduced level of aggression. He also accepted food without resistance. He agreed to participate in physical therapy 2 weeks after starting the risperidone treatment. Cognitive function also improved. He was discharged home 2 months after starting risperidone treatment and has subsequently been maintained on 3 mg/day of risperidone while pursuing outpatient rehabilitation programs.
Comment
The patient's refusal to eat and active resistance to instructions were considered to be catatonic signs.1 Catatonia is a clinical syndrome that has multiple causes.2 There is a case report of organic catatonia following frontal lobe injury;3 the patient's catatonic signs included stereotypic movements, iterations, and verbigerations, and she responded well to clozapine. Gamma-aminobutyric acid (GABA) receptors have been suggested to play a crucial role in catatonia,1 but the precise mechanisms by which psychotropic drugs relieve catatonic symptoms have not yet been elucidated.4 There is one case report of catatonic stupor and mutism that were successfully treated with risperidone;5 a CT scan in that case revealed bilateral orbitofrontal atrophy. Whatever the central mechanism, risperidone appears to be an effective treatment for patients who refuse to eat.
Further studies are needed to confirm the effectiveness of risperidone for the treatment of refusal to eat after TBI.
References
1.
Rosebush PI, Hildebrand AM, Furlong BG: Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation and response to lorazepam. J Clin Psychiatry 1990; 51:357-362
2.
Gomez EA, Comstock BS, Rosario A: Organic versus functional etiology in catatonia: case report. J Clin Psychiatry 1982; 43:200-201
3.
Rommel O, Tegenthoff M, Widdig W, et al: Organic catatonia following frontal lobe injury: response to clozapine. J Neuropsychiatry Clin Neurosci 1998; 10:237-238
4.
Kopala LC, Caudle C: Acute and long-term effects of risperidone in a case of first-episode catatonic schizophrenia. J Psychopharmacol 1998; 12:314-317
5.
Cook EH, Olson K, Pliskin N: Response of organic catatonia to risperidone. Arch Gen Psychiatry 1996; 53:82-83
Information & Authors
Information
Published In
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 87-a - 88
History
Published online: 1 February 2002
Published in print: February 2002
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).